Cystosure

Cystosure

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cystosure has developed the CystoSure® Plus, a novel medical device that combines a urinary catheter with a cystoscope port, creating a streamlined system for diagnostic bladder visualization. Founded by practicing physicians, the company addresses a century-old procedural gap by offering a faster, more standardized, and cost-effective alternative to traditional cystoscopy setups. Its value proposition centers on reducing surgical time, lowering infection risk, and enabling comprehensive bladder diagnostics in a single office visit, thereby improving workflow for clinicians and convenience for patients.

UrologyWomen's Health

Technology Platform

Patented integrated catheter-cystoscope system featuring a urinary catheter with a dedicated scope port and a pancake balloon for standardized bladder placement and visualization.

Opportunities

The primary opportunity is displacing outdated, cumbersome traditional cystoscopy setups in both hospital ORs and outpatient offices, driven by value propositions of time savings, reduced infection risk, and single-visit diagnostics.
Expansion into digital image capture/management and potential product iterations for adjacent procedures could provide growth avenues.

Risk Factors

Key risks include slow adoption by clinicians accustomed to traditional methods, potential competition from large, well-resourced medical device companies, and the inherent limitations of a product focused solely on female anatomy.
Regulatory compliance and product liability are ongoing concerns.

Competitive Landscape

Cystosure competes indirectly with traditional cystoscopy systems from major endoscopy companies (e.g., Olympus, Karl Storz) which are multi-component, non-integrated setups. Its direct competition is limited, as it pioneers the integrated catheter-scope niche for female patients, but it faces competition for capital expenditure budgets and procedural mindshare from these established players.